Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-DC in Advanced Solid Tumors
NCT07504445Phase 1Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FAP-targeted immunosuppressive CAR-DC in solid tumor (advanced stage), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Objective Response Rate at 2 years, Disease Control Rate at 2 years and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
FAP-targeted immunosuppressive CAR-DC
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07504445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504445.